Finland stops use of Moderna vaccines for men under 30

Moderna COVID-19 vaccinePhoto: AP Photo / Charlie Riedel / FILE
Advertisements

Finnish health authorities plan to stop vaccinating men under the age of 30 with the Moderna vaccine due to an increased incidence of heart inflammation.

The information was confirmed by the Institute for Health and Welfare (THL) at a press conference on Thursday, according to Yle.

“For the most part, myocarditis (inflammation of the heart muscle) is a mild, transient disease that requires follow-up for a few days,” director Mika Salminen at THL stated.

He says the most significant risk appears to be related to young men, after the second dose, but adds that fewer cases have been reported in Finland than, for example, Norway.

“For this reason, in accordance with the precautionary principle, THL believes that Moderna vaccine should not be given to men and boys under 30 years of age for the time being, but that they should rather take Pfizer’s vaccine,” Salminen said.

If they have already received Moderna as their first dose, the second dose should be Pfizer.

Salminen: Important to get the second dose

“It is still important that the second dose is taken,” Salminen emphasized.

Denmark and Sweden announced on Wednesday that they are stopping the Moderna vaccination of young people due to the increased risk of heart inflammation. In Norway, the health authorities issued a recommendation that men under 30 take the Pfizer vaccine instead of Moderna.

Inflammation of the heart is a rare side effect of mRNA vaccines. The risk is greatest among younger people, especially among young men. The risk of developing the rare symptom is also present in the Pfizer/BioNTech vaccine.

Source: © NTB Scanpix / #Norway Today / #NorwayTodayNews

Do you have a news tip for Norway Today? We want to hear it. Get in touch at info@norwaytoday.no

Advertisements

Be the first to comment on "Finland stops use of Moderna vaccines for men under 30"

Leave a comment

Your email address will not be published.


*